Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 663-8501, Japan.
Anticancer Res. 2012 Nov;32(11):4891-5.
Adenovirus vectors have been utilized for a variety of cancer gene therapy. The present study examined the oncolytic effect of adenovirus type 5 (Ad5) and fiber-substituted conditionally replicating adenovirus (CRAD) Ad5/F35 vectors on human lung cancer A549 cells (an epithelial adenocarcinoma cell line), SBC-3 cells (a small-cell cancer cell line), and Lu-65 cells (a giant-cell lung cancer cell line).
For adenovirus, the first mRNA/protein to be made (~1 h after infection) is early region 1A (E1A). Ad5F35 and Ad5 CRAD vectors containing the E1 gene, controlled by the human midkine promoter (Ad5F35/MKp-E1 and Ad5/MKp-E1, respectively) were constructed. Reverse transcription-polymerase chain reaction (RT-PCR), western blotting and cell viability assays were carried out in cells transfected with Ad5/MKp-E1 and Ad5F35/MKp-E1.
Less expression of mRNA and protein for coxsackie and adenovirus receptor (CAR), a cell surface target of Ad5, was found with lung cancer cells as compared with the expression in human embryonic kidney 293 (HEK293) cells, but otherwise mRNA and CD46 protein, a cell surface target of Ad35, was expressed in lung cancer cells as much as in HEK293 cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 induced oncolysis of lung cancer cells in a viral particle-dependent manner, with more efficient advantage for Ad5F35/MKp-E1.
The results of the present study suggest that Ad5F35/MKp-E1 is more useful for the gene therapy of human lung cancer than Ad5/MKp-E1 is.
腺病毒载体已被用于多种癌症的基因治疗。本研究探讨了腺病毒 5 型(Ad5)和纤维替代条件复制腺病毒(CRAD)Ad5/F35 载体对人肺癌 A549 细胞(上皮腺癌细胞系)、SBC-3 细胞(小细胞癌细胞系)和 Lu-65 细胞(巨细胞肺癌细胞系)的溶瘤作用。
对于腺病毒,第一个 mRNA/蛋白(感染后约 1 小时)是早期区域 1A(E1A)。构建了含有 E1 基因、受人中期因子启动子(Ad5F35/MKp-E1 和 Ad5/MKp-E1)控制的 Ad5F35 和 Ad5 CRAD 载体。在转染 Ad5/MKp-E1 和 Ad5F35/MKp-E1 的细胞中进行逆转录-聚合酶链反应(RT-PCR)、western blot 和细胞活力测定。
与人胚肾 293(HEK293)细胞相比,肺癌细胞中 Coxsackie 腺病毒受体(CAR)的 mRNA 和蛋白表达减少,CAR 是 Ad5 的细胞表面靶标,但肺癌细胞中 CD46 蛋白的 mRNA 表达与 HEK293 细胞一样多,CD46 蛋白是 Ad35 的细胞表面靶标。Ad5/MKp-E1 和 Ad5F35/MKp-E1 均以病毒颗粒依赖的方式诱导肺癌细胞溶瘤,Ad5F35/MKp-E1 具有更高的效率优势。
本研究结果表明,与 Ad5/MKp-E1 相比,Ad5F35/MKp-E1 更适合人类肺癌的基因治疗。